The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - Analysis of patient data in the prospective OVCAD study

Gynecologic Oncology

Volumn 131, Issue 1, 2013, Pages 15-20

  Hofstetter, G ^a   Concin, N ^a   Braicu, I ^b   Chekerov, R ^b   Sehouli, J ^b   Cadron, I ^c   Van Gorp, T ^d   Trillsch, F ^e   Mahner, S ^e   Ulmer, H ^a   Grimm, C ^f   Castillo Tong, D Cacsire ^f,g   Zeillinger, R ^f,g   Zeimet, A G ^a   Vergote, I ^c  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Katholieke Universiteit   (Belgium)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Ovarian cancer; Prognosis; Timing of chemotherapy

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY; OVARY CARCINOMA; OVERALL SURVIVAL; PEROPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; TIME TO TREATMENT;

EID: 84885294246     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.07.086     Document Type: Article

References (19)

1. Cannistra SA. Cancer of the ovary. N Engl J Med 2004;351: 2519-29.
2. Stuart GC, Kitchener H, Bacon M, duBois A, Friedlander M, Ledermann J, et al. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer 2011;21: 750-5.
3. Fisher B, Gunduz N, Saffer EA. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res 1983;43: 1488-92.
4. Lohrisch C, Paltiel C, Gelmon K, Speers C, Taylor S, Barnett J, et al. Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol 2006;24: 4888-94.
5. Biagi JJ, Raphael MJ, Wj Mackillop, Kong W, King WD, Booth CM. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis. JAMA 2011;305: 2335-42.
6. Rosa DD, Clamp A, Mullamitha S, Ton NC, Lau S, Byrd L, et al. The interval from surgery to chemotherapy in the treatment of advanced epithelial ovarian carcinoma. Eur J Surg Oncol 2006;32: 588-91.
7. Gadducci A, Sartori E, Landoni F, Zola P, Maggino T, Maggioni A, et al. Relationship between time interval from primary surgery to the start of taxane- plus platinum-based chemotherapy and clinical outcome of patients with advanced epithelial ovarian cancer: results of a multicentre retrospective Italian study. J Clin Oncol 2005;23: 751-8.
8. Aletti GD, Long HJ, Podratz KC, ClibyWA. Is time to chemotherapy a determinant of prognosis in advanced stage ovarian cancer? Gynecol Oncol 2007;104: 212-6.
9. Paulsen T, Kaern J, Kjaerheim K, Haldorsen T, Tropé C. Influence of interval between primary surgery and chemotherapy on short-term survival of patients with advanced ovarian, tubal or peritoneal cancer. Gynecol Oncol 2006;102: 447-52.
10. Flynn PM, Paul J, Cruickshank DJ, Scottish Gynaecological Cancer Trials Group. Does the interval from primary surgery to chemotherapy influence progression-free survival in ovarian cancer? Gynecol Oncol 2002;86: 354-7.
11. Warwick J, Kehoe S, Earl H, Luesley D, Redman C, Chan KK. Long-term follow-up of patients with advanced ovarian cancer treated in randomised clinical trials. Br J Cancer 1995;72: 1513-7.
12. Wright J, Doan T, McBride R, Jacobson J, Hershman D. Variability in chemotherapy delivery for elderly women with advanced stage ovarian cancer and its impact on survival. Br J Cancer 2008;98: 1197-203.
13. Wright JD, Herzog TJ, Neugut AI, Burke WM, Lu YS, Lewin SN, et al. Effect of radical cytoreductive surgery on omission and delay of chemotherapy for advance-stage ovarian cancer. Obstet Gynecol 2012;120: 871-81.
14. Mahner S, Eulenburg C, Staehle A, Wegscheider K, Reuss A, Pujade-Lauraine E, et al. Prognostic impact of the time interval between primary surgery and chemotherapy in patients with advanced ovarian cancer: analysis of prospective randomized phase III trials. Eur J Cancer 2013;49: 142-9.
15. Chekerov R, Braicu I, Castillo-Tong DC, Richter R, Cadron I, Mahner S, et al. Outcome and clinicalmanagement of 275 patients with advanced ovarian cancer International Federation of Obstetrics and Gynecology II to IV inside the European Ovarian Cancer Translational Research Consortium-OVCAD. Int J Gynecol Cancer 2013;23(2): 268-75.
16. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5: 649-55.
17. Li TS, Kaneda Y, Ueda K, Hamani K, Zempo N, Esato K. The influence of tumour resection on angiostatin levels and tumour growth - an experimental study in tumourbearing mice. Eur J Cancer 2001;37: 2283-8.
18. Hofer So, Shrayer D, Reichner JS,Hoekstra HJ,Wanebo HJ.Wound-induced tumor progression: a probable role in recurrence after tumor resection. Arch Surg 1998;133: 383-9.
19. Eggermont AM, Steller EP, Sugarbaker PH. Laparotomy enhances intraperitoneal tumor growth and abrogates the antitumor effects of interleukin-2 and lymphokine-activated killer cells. Surgery 1987;102: 71-8.